A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, non-inferiority trial
暂无分享,去创建一个
M. Bacharach | K. Kichikawa | F. Vermassen | W. Gray | H. Deutschmann | D. Scheinert | M. Jaff | J. Popma | C. Loewe | K. Ando | Masato Nakamura | H. Yokoi | S. Jaalouk | A. Miyamoto | T. Zeller | T. Albrecht | T. Ohki | P. O. Simon | S. Müller-Hülsbeck | D. Bajakian | T. Mano | P. Hall | L. Garcia | S. Hawkins | Y. Yokoi | D. Kawasaki | S. Janzer | R. Rhee | R. Feldman | Gagan D Singh | Andrew J Benko | M. Werner | Y. Soga | K. Hirano | J. Diaz-Cartelle | T. Vasudevan | James Park | T. Das | A. Babaev | J. Benenati | E. Korngold | A. Holden | K. Tan | W. Bachinsky | R. Mendes | H. Schroë | J. Ricci | M. Burket | D. Dulas | B. Wiechmann | Steve Henao | R. Beasley | L. Lopez | K. Keirse | H. Schroeder | J. Golzar | Jeffery T Prem | Joseph Cardenas | R. D. Martino | Mark W. Fugate | R. Gutta | B. Herdrich | Yazan Khatib | Henry H Lui | David O’Connor | R. Powell | Antonis Pratsos | Vikram Rao | John Rashid | P. Tolerico | Andrew Benko | Robert E. Beasley | Gagan D. Singh | Jeffery T Prem | Jeffery Prem | Henrik Schroeder | Louis Lopez | Henry H. Lui | Thodur M. Vasudevan
[1] T. Bisdas,et al. 1-Year All-Comers Analysis of the Eluvia Drug-Eluting Stent for Long Femoropopliteal Lesions After Suboptimal Angioplasty. , 2018, JACC. Cardiovascular interventions.
[2] D. Scheinert,et al. 12-Month Results From the First-in-Human Randomized Study of the Ranger Paclitaxel-Coated Balloon for Femoropopliteal Treatment. , 2018, JACC. Cardiovascular interventions.
[3] A Ross Naylor,et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed b , 2018, European heart journal.
[4] P. Teirstein,et al. Long-Term Safety and Efficacy of Platinum Chromium Everolimus-Eluting Stents in Coronary Artery Disease: 5-Year Results From the PLATINUM Trial. , 2017, JACC. Cardiovascular interventions.
[5] Thomas Zeller,et al. Long-Term Results from the MAJESTIC Trial of the Eluvia Paclitaxel-Eluting Stent for Femoropopliteal Treatment: 3-Year Follow-up , 2017, CardioVascular and Interventional Radiology.
[6] P. Faries,et al. Stellarex Drug-Coated Balloon for Treatment of Femoropopliteal Disease , 2017, Circulation.
[7] C. Paetzel,et al. The 24-Month Results of the Lutonix Global SFA Registry: Worldwide Experience With Lutonix Drug-Coated Balloon. , 2017, JACC. Cardiovascular interventions.
[8] D. Kroetz,et al. Clinical Pharmacokinetics of Paclitaxel Monotherapy: An Updated Literature Review , 2017, Clinical Pharmacokinetics.
[9] T. Zeller,et al. Twelve-Month Results From the MAJESTIC Trial of the Eluvia Paclitaxel-Eluting Stent for Treatment of Obstructive Femoropopliteal Disease , 2016, Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists.
[10] M. Dake,et al. Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery , 2016, Circulation.
[11] D. Scheinert,et al. Trial of a Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease. , 2015, The New England journal of medicine.
[12] V. Aboyans,et al. Epidemiology of peripheral artery disease. , 2015, Circulation research.
[13] J. Massaro,et al. Supervised exercise, stent revascularization, or medical therapy for claudication due to aortoiliac peripheral artery disease: the CLEVER study. , 2015, Journal of the American College of Cardiology.
[14] D. Scheinert,et al. Drug-Coated Balloon Versus Standard Percutaneous Transluminal Angioplasty for the Treatment of Superficial Femoral and Popliteal Peripheral Artery Disease , 2015, Circulation.
[15] Nancy M Albert,et al. Management of patients with peripheral artery disease (compilation of 2005 and 2011 ACCF/AHA guideline recommendations): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Circulation.
[16] John V. White,et al. Management of patients with peripheral artery disease (compilation of 2005 and 2011 ACCF/AHA Guideline Recommendations): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.
[17] M. Dake,et al. Nitinol Stents With Polymer-Free Paclitaxel Coating for Lesions in the Superficial Femoral and Popliteal Arteries Above the Knee: Twelve-Month Safety and Effectiveness Results From the Zilver PTX Single-Arm Clinical Study , 2011, Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists.
[18] H. Yokoi,et al. Timing of the restenosis following nitinol stenting in the superficial femoral artery and the factors associated with early and late restenoses , 2011, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[19] M. Dake,et al. Paclitaxel-Eluting Stents Show Superiority to Balloon Angioplasty and Bare Metal Stents in Femoropopliteal Disease: Twelve-Month Zilver PTX Randomized Study Results , 2011, Circulation. Cardiovascular interventions.
[20] Thomas Zeller,et al. First clinical trial of nitinol self-expanding everolimus-eluting stent implantation for peripheral arterial occlusive disease. , 2011, Journal of vascular surgery.
[21] M. Dake,et al. Polymer-free paclitaxel-coated Zilver PTX Stents--evaluation of pharmacokinetics and comparative safety in porcine arteries. , 2011, Journal of vascular and interventional radiology : JVIR.
[22] Gregg W Stone,et al. A prospective, randomized evaluation of a novel everolimus-eluting coronary stent: the PLATINUM (a Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System [PROMUS Element] for the Treatment of Up to Two de Novo Coronary Artery Lesions) trial. , 2011, Journal of the American College of Cardiology.
[23] R. Dayal,et al. An analysis of the outcomes of a decade of experience with lower extremity revascularization including limb salvage, lengths of stay, and safety. , 2010, Journal of vascular surgery.
[24] L. Norgren,et al. Inter-society consensus for the management of peripheral arterial disease. , 2007, International angiology : a journal of the International Union of Angiology.
[25] D. Bloch,et al. Performance goals and endpoint assessments for clinical trials of femoropopliteal bare nitinol stents in patients with symptomatic peripheral arterial disease , 2007, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[26] L. Norgren,et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). , 2007, Journal of vascular surgery.
[27] Jean-Paul Beregi,et al. Drug-Eluting and Bare Nitinol Stents for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery: Long-Term Results from the SIROCCO Trial , 2006, Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists.
[28] R. Rutherford,et al. Recommended standards for reports dealing with lower extremity ischemia: revised version. , 1997, Journal of vascular surgery.